Understanding High-Risk MDS (and Transition to AML) | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Understanding High-Risk MDS (and Transition to AML)

Related Bone Marrow Failure Diseases and Malignancies
Bone Marrow Transplant
Myelodysplastic Syndromes (MDS)
Managing Your Treatment
Acute Myeloid Leukemia (AML)
Presentation Date: 
Sat, 09/11/2021 - 10:30am (EDT)

This session is suitable for patients, family members, and caregivers who are living with a diagnosis of higher risk MDS and who may (or already have) transition to AML. Dr. Jay Lang will discuss how your hematologist/oncologist arrives at the diagnosis and how they determine the best course of treatment including an assessment of the factors that go into making that determination (i.e. age, overall health, IPSS-R score, mutations, availability of treatment options, patient preferences). He will also talk about transplant vs. non-transplant options and the prognosis for patients before, during and after treatment.